{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:36:01Z","timestamp":1790933761878,"version":"4.1.0"},"reference-count":13,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,10,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To compare the long-term outcome of patients with previously untreated follicular lymphoma (FL) needing therapy, after treatment with cyclophosphamide, vincristine and prednisone (CVP) versus CVP plus rituximab (R-CVP) and to evaluate the predictive value of known prognostic factors after treatment with R-CVP. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients with previously untreated CD20-positive stage III\/IV FL were randomly assigned to eight cycles of R-CVP (n = 159) or CVP alone (n = 162). The median follow-up period was 53 months. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> The primary end point\u2014time to treatment failure (TTF), which included patients without a response after four cycles as an event\u2014was significantly prolonged in patients receiving R-CVP versus CVP (P &lt; .0001). Improvements in all other end points, including overall and complete response rates (P &lt; .0001), time to progression (TTP; P &lt; .0001), response duration (P &lt; .0001), time to next antilymphoma treatment (P &lt; .0001), and overall survival (OS; P = .029; 4-year OS: 83% v 77%;) were achieved with R-CVP versus CVP alone. Univariate analyses demonstrated an improvement in TTP with R-CVP versus CVP irrespective of the Follicular Lymphoma International Prognostic Index (FLIPI) subgroup, the International Prognostic Index (IPI) subgroup, baseline histology, and the presence or absence of B symptoms or bulky disease. By multivariate analysis, FLIPI retains a strong predictive power for TTP in the presence of the trial treatment effect. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Analysis of all outcome measures, including OS, confirm the benefit of adding R to CVP in the front-line treatment of FL. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2007.13.5376","type":"journal-article","created":{"date-parts":[[2008,7,29]],"date-time":"2008-07-29T00:33:51Z","timestamp":1217291631000},"page":"4579-4586","source":"Crossref","is-referenced-by-count":512,"title":["Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma"],"prefix":"10.1200","volume":"26","author":[{"given":"Robert","family":"Marcus","sequence":"first","affiliation":[{"name":"From the Department of Hematology, Addenbrooke's Hospital, Cambridge; Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Department of Medicine Toronto\u2013Sunnybrook Regional Cancer Centre, Toronto, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; Department of Hematology and Medical Oncology, Clinique Victor Hugo, Le Mans, France; Department of Hematology, Monash Medical Centre, Clayton, Victoria, Australia; Department of Hematology, Medical University of Lublin,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Imrie","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Addenbrooke's Hospital, Cambridge; Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Department of Medicine Toronto\u2013Sunnybrook Regional Cancer Centre, Toronto, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; Department of Hematology and Medical Oncology, Clinique Victor Hugo, Le Mans, France; Department of Hematology, Monash Medical Centre, Clayton, Victoria, Australia; Department of Hematology, Medical University of Lublin,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Solal-Celigny","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Addenbrooke's Hospital, Cambridge; Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Department of Medicine Toronto\u2013Sunnybrook Regional Cancer Centre, Toronto, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; Department of Hematology and Medical Oncology, Clinique Victor Hugo, Le Mans, France; Department of Hematology, Monash Medical Centre, Clayton, Victoria, Australia; Department of Hematology, Medical University of Lublin,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Catalano","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Addenbrooke's Hospital, Cambridge; Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Department of Medicine Toronto\u2013Sunnybrook Regional Cancer Centre, Toronto, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; Department of Hematology and Medical Oncology, Clinique Victor Hugo, Le Mans, France; Department of Hematology, Monash Medical Centre, Clayton, Victoria, Australia; Department of Hematology, Medical University of Lublin,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dmoszynska","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Addenbrooke's Hospital, Cambridge; Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Department of Medicine Toronto\u2013Sunnybrook Regional Cancer Centre, Toronto, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; Department of Hematology and Medical Oncology, Clinique Victor Hugo, Le Mans, France; Department of Hematology, Monash Medical Centre, Clayton, Victoria, Australia; Department of Hematology, Medical University of Lublin,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o C.","family":"Raposo","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Addenbrooke's Hospital, Cambridge; Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Department of Medicine Toronto\u2013Sunnybrook Regional Cancer Centre, Toronto, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; Department of Hematology and Medical Oncology, Clinique Victor Hugo, Le Mans, France; Department of Hematology, Monash Medical Centre, Clayton, Victoria, Australia; Department of Hematology, Medical University of Lublin,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz C.","family":"Offner","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Addenbrooke's Hospital, Cambridge; Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Department of Medicine Toronto\u2013Sunnybrook Regional Cancer Centre, Toronto, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; Department of Hematology and Medical Oncology, Clinique Victor Hugo, Le Mans, France; Department of Hematology, Monash Medical Centre, Clayton, Victoria, Australia; Department of Hematology, Medical University of Lublin,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Gomez-Codina","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Addenbrooke's Hospital, Cambridge; Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Department of Medicine Toronto\u2013Sunnybrook Regional Cancer Centre, Toronto, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; Department of Hematology and Medical Oncology, Clinique Victor Hugo, Le Mans, France; Department of Hematology, Monash Medical Centre, Clayton, Victoria, Australia; Department of Hematology, Medical University of Lublin,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Belch","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Addenbrooke's Hospital, Cambridge; Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Department of Medicine Toronto\u2013Sunnybrook Regional Cancer Centre, Toronto, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; Department of Hematology and Medical Oncology, Clinique Victor Hugo, Le Mans, France; Department of Hematology, Monash Medical Centre, Clayton, Victoria, Australia; Department of Hematology, Medical University of Lublin,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Addenbrooke's Hospital, Cambridge; Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Department of Medicine Toronto\u2013Sunnybrook Regional Cancer Centre, Toronto, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; Department of Hematology and Medical Oncology, Clinique Victor Hugo, Le Mans, France; Department of Hematology, Monash Medical Centre, Clayton, Victoria, Australia; Department of Hematology, Medical University of Lublin,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Wassner-Fritsch","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Addenbrooke's Hospital, Cambridge; Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Department of Medicine Toronto\u2013Sunnybrook Regional Cancer Centre, Toronto, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; Department of Hematology and Medical Oncology, Clinique Victor Hugo, Le Mans, France; Department of Hematology, Monash Medical Centre, Clayton, Victoria, Australia; Department of Hematology, Medical University of Lublin,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Stein","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Addenbrooke's Hospital, Cambridge; Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Department of Medicine Toronto\u2013Sunnybrook Regional Cancer Centre, Toronto, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; Department of Hematology and Medical Oncology, Clinique Victor Hugo, Le Mans, France; Department of Hematology, Monash Medical Centre, Clayton, Victoria, Australia; Department of Hematology, Medical University of Lublin,..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.146"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.110.110"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Hochster HS, Weller E, Gascoyne RD, et al: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 Phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 106:106a,2005,  (abstr)","DOI":"10.1182\/blood.V106.11.349.349"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi320"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.164"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-013367"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2007.13.5376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:21:05Z","timestamp":1653510065000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.13.5376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,1]]},"references-count":13,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2008,10,1]]}},"alternative-id":["10.1200\/JCO.2007.13.5376"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.13.5376","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,1]]}}}